We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Tools to Study Genomic Instability

Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "Tools to Study Genomic Instability"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

AMSBIO has announced a new second generation PARP in vivo Pharmacodynamic Assay that accurately measures net poly (ADP-ribose) (PAR) levels in cellular extracts and has been used to document differences in PAR levels in human tumor lysates from a variety of tissues, organs and xenografts.

Poly-ADP-ribose polymerase (PARP) is a protein involved in a number of cellular processes including catalyzing the NAD-dependent addition of PAR onto itself and other adjacent nuclear proteins. PARP-1 is widely regarded as a promising target for the development of drugs useful in various regimes of cancer therapy, inflammation, ischemia and neurodegeneration. More recently the discovery that breast cancers deficient in homologous recombination are sensitive to non-toxic PARP inhibitors has resulted in efforts by numerous pharmaceutical companies to develop PARP-1 specific drugs.

AMSBIO's PARP in vivo Pharmacodynamic Assay uses a validated sample processing regime and a chemiluminescent, sandwich ELISA format, with pre-coated 96-stripwell plates. The Assay reports PAR level with high signal to noise ratio; sensitivity of 2 pg/ml and a linear dynamic range to 1000 pg/ml. Consequently the PARP in vivo Pharmacodynamic Assay offers an exciting new tool that provides evidence of drug action on molecular targets and generates baseline values that may be used to stratify patient response to therapy.